Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$231.00K$231.00Kderived−48.1% vs Q4 2023 Net Income-$28.22M-$28.22MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$18,499,000N/M Operating Cash Flowderived-$20,181,000N/M Free Cash Flowderived-$20,259,000— Margins · derivedOperating margin-8008.2%−4605.5 pt vs Q4 2023
Net margin-12217.7%−7966.3 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 31, 2025 · 90 d after period end